ArticleCureus2022
Acute Portal Vein Thrombosis Secondary to COVID-19 Vaccination.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
- New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review.BMC gastroenterology · 2022Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein thrombosis (PVT) is a partial or complete occlusion of the hepatic portal vein most frequently seen in patients with cirrhotic liver disease. Various non-cirrhotic conditions including inherited prothrombic blood disorders, neoplasms, and inflammatory diseases create hypercoagulable states that predispose individuals to blood clotting. Rarely does an exhaustive workup leave the etiology of a PVT unknown or unclear, and even more uncommon is a potential new etiology suspected. Our patient is a 34-year-old female, with no significant risk factors for pathologic clotting, who was diagnosed with an acute PVT several days after receiving the Moderna coronavirus disease 2019 (COVID-19) vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.